MLi-2

€177.00

Excl. VAT

Item no.	HY-100411-5mg
Manufacturer	MedChem Express
CASRN	1627091-47-7
Amount	5 mg
Category	Oncology Neuroscience Neuroinflammation Neural Mitochondrial Function Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Purity	99.80
Formula	C21H25N5O2
Citations	[1]Fell MJ, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409.
Smiles	C[C@@](C1)([H])O[C@](C)([H])CN1C2=CC(C3=NNC4=CC=C(OC5(C)CC5)C=C43)=NC=N2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1627091-47-7
Available
Product Description	MLi-2 is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neurodegeneration
Molecular Weight	379.46
Clinical Information	No Development Reported
Solubility	DMSO : 50 mg/mL (ultrasonic)
Pathway	Autophagy
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100411-5mg-safety-datasheet.pdf